Global Irritable Bowel Syndrome (IBS) 麻豆原创 2025 by Company, Regions, Type and Application, Forecast to 2031

Publication ID:

GIR062510884

Publication Date:

June 30, 2025

Pages:

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Irritable Bowel Syndrome (IBS) market size was valued at US$ 6433 million in 2024 and is forecast to a readjusted size of USD 16580 million by 2031 with a CAGR of 14.6% during review period.
Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.
North America is the largest region of Irritable Bowel Syndrome (IBS), with a market share about 75%. Allergan, Valeant Pharmaceuticals, Takeda, Sucampo Pharmaceuticals and McNeil Consumer Healthcare are the top 5 manufacturers of industry, and they had about 80% combined market share.
This report is a detailed and comprehensive analysis for global Irritable Bowel Syndrome (IBS) market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Irritable Bowel Syndrome (IBS) market size and forecasts, in consumption value ($ Million), 2020-2031
Global Irritable Bowel Syndrome (IBS) market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Irritable Bowel Syndrome (IBS) market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Irritable Bowel Syndrome (IBS) market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Irritable Bowel Syndrome (IBS)
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Irritable Bowel Syndrome (IBS) market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bausch Health, Allergan, Takeda, Sucampo Pharmaceuticals (Mallinckrodt), Sebela Pharmaceuticals Inc, Astellas Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Irritable Bowel Syndrome (IBS) market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
IBS-D Drug
IBS-C Drug
Others
麻豆原创 segment by Application
Women
Men
麻豆原创 segment by players, this report covers
Bausch Health
Allergan
Takeda
Sucampo Pharmaceuticals (Mallinckrodt)
Sebela Pharmaceuticals Inc
Astellas Pharmaceuticals
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Irritable Bowel Syndrome (IBS) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Irritable Bowel Syndrome (IBS), with revenue, gross margin, and global market share of Irritable Bowel Syndrome (IBS) from 2020 to 2025.
Chapter 3, the Irritable Bowel Syndrome (IBS) competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Irritable Bowel Syndrome (IBS) market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Irritable Bowel Syndrome (IBS).
Chapter 13, to describe Irritable Bowel Syndrome (IBS) research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Irritable Bowel Syndrome (IBS) by Type
1.3.1 Overview: Global Irritable Bowel Syndrome (IBS) 麻豆原创 Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Irritable Bowel Syndrome (IBS) Consumption Value 麻豆原创 Share by Type in 2024
1.3.3 IBS-D Drug
1.3.4 IBS-C Drug
1.3.5 Others
1.4 Global Irritable Bowel Syndrome (IBS) 麻豆原创 by Application
1.4.1 Overview: Global Irritable Bowel Syndrome (IBS) 麻豆原创 Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Women
1.4.3 Men
1.5 Global Irritable Bowel Syndrome (IBS) 麻豆原创 Size & Forecast
1.6 Global Irritable Bowel Syndrome (IBS) 麻豆原创 Size and Forecast by Region
1.6.1 Global Irritable Bowel Syndrome (IBS) 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Irritable Bowel Syndrome (IBS) 麻豆原创 Size by Region, (2020-2031)
1.6.3 North America Irritable Bowel Syndrome (IBS) 麻豆原创 Size and Prospect (2020-2031)
1.6.4 Europe Irritable Bowel Syndrome (IBS) 麻豆原创 Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Irritable Bowel Syndrome (IBS) 麻豆原创 Size and Prospect (2020-2031)
1.6.6 South America Irritable Bowel Syndrome (IBS) 麻豆原创 Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Irritable Bowel Syndrome (IBS) 麻豆原创 Size and Prospect (2020-2031)
2 Company Profiles
2.1 Bausch Health
2.1.1 Bausch Health Details
2.1.2 Bausch Health Major Business
2.1.3 Bausch Health Irritable Bowel Syndrome (IBS) Product and Solutions
2.1.4 Bausch Health Irritable Bowel Syndrome (IBS) Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Bausch Health Recent Developments and Future Plans
2.2 Allergan
2.2.1 Allergan Details
2.2.2 Allergan Major Business
2.2.3 Allergan Irritable Bowel Syndrome (IBS) Product and Solutions
2.2.4 Allergan Irritable Bowel Syndrome (IBS) Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Allergan Recent Developments and Future Plans
2.3 Takeda
2.3.1 Takeda Details
2.3.2 Takeda Major Business
2.3.3 Takeda Irritable Bowel Syndrome (IBS) Product and Solutions
2.3.4 Takeda Irritable Bowel Syndrome (IBS) Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Takeda Recent Developments and Future Plans
2.4 Sucampo Pharmaceuticals (Mallinckrodt)
2.4.1 Sucampo Pharmaceuticals (Mallinckrodt) Details
2.4.2 Sucampo Pharmaceuticals (Mallinckrodt) Major Business
2.4.3 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Product and Solutions
2.4.4 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Sucampo Pharmaceuticals (Mallinckrodt) Recent Developments and Future Plans
2.5 Sebela Pharmaceuticals Inc
2.5.1 Sebela Pharmaceuticals Inc Details
2.5.2 Sebela Pharmaceuticals Inc Major Business
2.5.3 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Product and Solutions
2.5.4 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Sebela Pharmaceuticals Inc Recent Developments and Future Plans
2.6 Astellas Pharmaceuticals
2.6.1 Astellas Pharmaceuticals Details
2.6.2 Astellas Pharmaceuticals Major Business
2.6.3 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Product and Solutions
2.6.4 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Astellas Pharmaceuticals Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Irritable Bowel Syndrome (IBS) Revenue and Share by Players (2020-2025)
3.2 麻豆原创 Share Analysis (2024)
3.2.1 麻豆原创 Share of Irritable Bowel Syndrome (IBS) by Company Revenue
3.2.2 Top 3 Irritable Bowel Syndrome (IBS) Players 麻豆原创 Share in 2024
3.2.3 Top 6 Irritable Bowel Syndrome (IBS) Players 麻豆原创 Share in 2024
3.3 Irritable Bowel Syndrome (IBS) 麻豆原创: Overall Company Footprint Analysis
3.3.1 Irritable Bowel Syndrome (IBS) 麻豆原创: Region Footprint
3.3.2 Irritable Bowel Syndrome (IBS) 麻豆原创: Company Product Type Footprint
3.3.3 Irritable Bowel Syndrome (IBS) 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Irritable Bowel Syndrome (IBS) Consumption Value and 麻豆原创 Share by Type (2020-2025)
4.2 Global Irritable Bowel Syndrome (IBS) 麻豆原创 Forecast by Type (2026-2031)
5 麻豆原创 Size Segment by Application
5.1 Global Irritable Bowel Syndrome (IBS) Consumption Value 麻豆原创 Share by Application (2020-2025)
5.2 Global Irritable Bowel Syndrome (IBS) 麻豆原创 Forecast by Application (2026-2031)
6 North America
6.1 North America Irritable Bowel Syndrome (IBS) Consumption Value by Type (2020-2031)
6.2 North America Irritable Bowel Syndrome (IBS) 麻豆原创 Size by Application (2020-2031)
6.3 North America Irritable Bowel Syndrome (IBS) 麻豆原创 Size by Country
6.3.1 North America Irritable Bowel Syndrome (IBS) Consumption Value by Country (2020-2031)
6.3.2 United States Irritable Bowel Syndrome (IBS) 麻豆原创 Size and Forecast (2020-2031)
6.3.3 Canada Irritable Bowel Syndrome (IBS) 麻豆原创 Size and Forecast (2020-2031)
6.3.4 Mexico Irritable Bowel Syndrome (IBS) 麻豆原创 Size and Forecast (2020-2031)
7 Europe
7.1 Europe Irritable Bowel Syndrome (IBS) Consumption Value by Type (2020-2031)
7.2 Europe Irritable Bowel Syndrome (IBS) Consumption Value by Application (2020-2031)
7.3 Europe Irritable Bowel Syndrome (IBS) 麻豆原创 Size by Country
7.3.1 Europe Irritable Bowel Syndrome (IBS) Consumption Value by Country (2020-2031)
7.3.2 Germany Irritable Bowel Syndrome (IBS) 麻豆原创 Size and Forecast (2020-2031)
7.3.3 France Irritable Bowel Syndrome (IBS) 麻豆原创 Size and Forecast (2020-2031)
7.3.4 United Kingdom Irritable Bowel Syndrome (IBS) 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Russia Irritable Bowel Syndrome (IBS) 麻豆原创 Size and Forecast (2020-2031)
7.3.6 Italy Irritable Bowel Syndrome (IBS) 麻豆原创 Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Irritable Bowel Syndrome (IBS) Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Irritable Bowel Syndrome (IBS) Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Irritable Bowel Syndrome (IBS) 麻豆原创 Size by Region
8.3.1 Asia-Pacific Irritable Bowel Syndrome (IBS) Consumption Value by Region (2020-2031)
8.3.2 China Irritable Bowel Syndrome (IBS) 麻豆原创 Size and Forecast (2020-2031)
8.3.3 Japan Irritable Bowel Syndrome (IBS) 麻豆原创 Size and Forecast (2020-2031)
8.3.4 South Korea Irritable Bowel Syndrome (IBS) 麻豆原创 Size and Forecast (2020-2031)
8.3.5 India Irritable Bowel Syndrome (IBS) 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Southeast Asia Irritable Bowel Syndrome (IBS) 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Australia Irritable Bowel Syndrome (IBS) 麻豆原创 Size and Forecast (2020-2031)
9 South America
9.1 South America Irritable Bowel Syndrome (IBS) Consumption Value by Type (2020-2031)
9.2 South America Irritable Bowel Syndrome (IBS) Consumption Value by Application (2020-2031)
9.3 South America Irritable Bowel Syndrome (IBS) 麻豆原创 Size by Country
9.3.1 South America Irritable Bowel Syndrome (IBS) Consumption Value by Country (2020-2031)
9.3.2 Brazil Irritable Bowel Syndrome (IBS) 麻豆原创 Size and Forecast (2020-2031)
9.3.3 Argentina Irritable Bowel Syndrome (IBS) 麻豆原创 Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Irritable Bowel Syndrome (IBS) Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Irritable Bowel Syndrome (IBS) Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Irritable Bowel Syndrome (IBS) 麻豆原创 Size by Country
10.3.1 Middle East & Africa Irritable Bowel Syndrome (IBS) Consumption Value by Country (2020-2031)
10.3.2 Turkey Irritable Bowel Syndrome (IBS) 麻豆原创 Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Irritable Bowel Syndrome (IBS) 麻豆原创 Size and Forecast (2020-2031)
10.3.4 UAE Irritable Bowel Syndrome (IBS) 麻豆原创 Size and Forecast (2020-2031)
11 麻豆原创 Dynamics
11.1 Irritable Bowel Syndrome (IBS) 麻豆原创 Drivers
11.2 Irritable Bowel Syndrome (IBS) 麻豆原创 Restraints
11.3 Irritable Bowel Syndrome (IBS) Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Irritable Bowel Syndrome (IBS) Industry Chain
12.2 Irritable Bowel Syndrome (IBS) Upstream Analysis
12.3 Irritable Bowel Syndrome (IBS) Midstream Analysis
12.4 Irritable Bowel Syndrome (IBS) Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Companies Mentioned:

Bausch Health
Allergan
Takeda
Sucampo Pharmaceuticals (Mallinckrodt)
Sebela Pharmaceuticals Inc
Astellas Pharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.